Dr. Renato Martins on the Effects of Nivolumab and Ipilimumab

Published: Saturday, Nov 07, 2015

Renato G. Martins, MD, MPH, medical director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, Fred Hutch Professor, University of Washington School of Medicine, discusses the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti–CTLA-4, in the treatment of lung cancer.

Martins says there are patients who were treated with nivolumab and ipilimumab years ago that have not had a recurrence of lung cancer. He says the effects of nivolumab and ipilimumab are “unprecedented” and that the combination of the positive side effect profile and the quality of the responses have made medical professionals particularly enthusiastic.

Renato G. Martins, MD, MPH, medical director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, Fred Hutch Professor, University of Washington School of Medicine, discusses the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti–CTLA-4, in the treatment of lung cancer.

Martins says there are patients who were treated with nivolumab and ipilimumab years ago that have not had a recurrence of lung cancer. He says the effects of nivolumab and ipilimumab are “unprecedented” and that the combination of the positive side effect profile and the quality of the responses have made medical professionals particularly enthusiastic.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x